A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)

NCT07555483 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Alpha 1 Antitrypsin Deficiency

Interventions

DRUG: Alpha-1 15%
OTHER: Liquid Alpha1-PI

Sponsor

Grifols Therapeutics LLC